Standout Papers

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes 2021 2026 2022 20241.0k
  1. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021)
    Juan P. Frías, Melanie J. Davies et al. New England Journal of Medicine
  2. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial (2021)
    Bernhard Ludvik, Francesco Giorgino et al. The Lancet

Immediate Impact

5 from Science/Nature 87 standout
Sub-graph 1 of 19

Citing Papers

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
2024 Standout
Adipose tissue retains an epigenetic memory of obesity after weight loss
2024 StandoutNature
1 intermediate paper

Works of Katelyn Brown being referenced

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
2021 Standout

Author Peers

Author Last Decade Papers Cites
Katelyn Brown 1275 577 422 543 22 1.6k
Ross Bray 1425 642 422 501 20 1.7k
Jesper Madsen 1240 430 336 440 28 1.9k
Jason Brett 1675 807 621 410 17 1.9k
Daniel R. Quast 967 469 437 268 30 1.4k
Ángel Rodríguez 1148 439 287 406 39 1.4k
Mads Axelsen 926 510 380 324 14 1.6k
Matthew Wintle 1393 611 561 296 18 1.6k
Breno Edson Sendão Alves 944 324 368 688 9 1.6k
Kristian Kandler 687 319 281 549 22 1.4k
Trine Vang Skjøth 1054 371 330 592 23 1.3k

All Works

Loading papers...

Rankless by CCL
2026